Feb 26, 2025 / 12:00PM GMT
Operator
Greetings and welcome to the Nykode, Q4 2024 Financial Results webcast. At this time, all participants are going to listen-only mode.
(Operator Instructions)
It's my pleasure to turn the call over to your CEO Michael Engsig. Please go ahead.
Michael Engsig - Nykode Therapeutics ASA - Chief Executive Officer
Thank you very much, Kevin. And also from my side, I want welcome to all the participants for this IO's 4th quarter webcast. Just a quick reminder of our, fraud statement. We assume you're all familiar with those on that note, we'll move forward.
I am very pleased to, as usual, have Agnete Fredrickson, Chief Scientific Officer, head of business development, and co-founder, with me together with Harold Gurvin, Chief Financial Officer together. We'll take you through the key highlights of the fourth quarter. As well as, of course, the financial numbers. So, it's been an eventful, fourth quarter for us. Although obviously there are parts of this, we are not looking forward to see, any time through. It has been a tough, period with, a
Q4 2024 Nykode Therapeutics ASA Earnings Call Transcript
Feb 26, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers